Gene editing reminds professionals and the public that this technology’s reach goes beyond treating somatic disease to germline consequences yet unknown.
AMA J Ethics. 2019;21(12):E1056-1058. doi:
10.1001/amajethics.2019.1056.
International debate about human genome editing governance has undergone a paradigm shift and suggests that inclusive public deliberation is still important.
AMA J Ethics. 2019;21(12):E1065-1070. doi:
10.1001/amajethics.2019.1065.
A look at current literature and work by a statewide initiative can motivate development of policies that help respond to unrepresented patients’ needs.
AMA J Ethics. 2019;21(7):E611-616. doi:
10.1001/amajethics.2019.611.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.